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Abstract 
 
AIM: 
(i)To describe the prevalence of benzodiazepine use in Belgian nursing homes, with specific attention to indications 
and dosages. 
(ii)To compare actual and recommended dosages of benzodiazepines for anxiety and insomnia. 
(iii)To explore the risk profile for chronic benzodiazepine use in institutionalised older adults. 
METHODS: 
Medication charts of 1730 residents from 76 nursing homes in Belgium were collected and analysed, using the ATC 
classification. Drug name, indication and daily dosage were recorded. From authoritative international sources, we 
extracted for each drug and each indication a daily dosage recommended not to exceed in older adults, for 
comparison with observed actual dosages. 
RESULTS: 
Among the chronic BZD/Z users (50% of the residents), the leading indication was ‘insomnia’ (59% of the users) 
followed by ‘anxiety’ (17%) and ‘unrest’ (10%). In the chronic prescriptions of BZD/Zs indicated for insomnia, the 
actual daily dose exceeded the geriatric upper limit: with lormetazepam in 95% ,zolpidem in 82%, zopiclone in 78% 
and lorazepam in 35% of the prescriptions. In anxiety, daily doses also exceeded the limit but not to the same 
extend. 
Multivariate analysis showed BZD/Z use was positively associated with pain (OR 1.58 CI95% 1.27-1.97), constipation 
(OR 1.43 CI95% 1.16-1.76) and depression (OR 1.68 CI95% 1.35-2.08). Residents with dementia were less likely of 
receiving a BZD/Z (OR 0.60 CI95% 0.48-0.74). 
CONCLUSION: 
Efforts to reduce the use of BZD/Zs in nursing homes should concentrate on insomnia, with interventions aimed to 
reduce too high prevalence of chronic use and too high daily dosages in this indication. 
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INTRODUCTION 
Benzodiazepine utilisation in older adults is high, with intake rates varying from 28% to 55% in European nursing 
homes [1-4].    
Benzodiazepines are mainly indicated for the short-term treatment of insomnia and anxiety [5, 6]. Long-term use of 
benzodiazepines is discouraged in guidelines [5, 7, 8] because of the lack of effectiveness after 4 weeks [9, 10], the 
increased risk of dependence and abuse,  and withdrawal syndromes [11, 12]. Moreover, it has been hypothesised 
that long-term use might have a detrimental effect on cognition and a potential acceleration of cognitive 
impairment [13-15].  
High benzodiazepine utilisation in older adults is especially worrying,  since age-related pharmacokinetic-and 
dynamic alterations may lead to an increased risk of amnesia, confusion, sedation [16, 17], hangover effects [18, 
19] and consecutive risk of falling [20].   
International drug formularies [21-23] recommend dose reduction when using benzodiazepines in older adults. 
Moreover, in several attempts to develop prescribing quality indicators, upper limits for dosages in older adults 
were established for some benzodiazepines as part of lists with explicit criteria for inappropriate prescribing [24-
26]. In addition, benzodiazepines are the most recurring group of drugs in terms of chronic prescribing and in terms 
of inappropriate psychotropic polypharmacy.  
Numerous studies have explored benzodiazepine utilisation in older adults, but they are often limited to the 
description of crude utilisation data, without looking deeper into active substances, dosages and indications. 
Previous articles indicate the need for documentation of indications to proper evaluate the appropriateness of 
psychotropic drug use  [27, 28].  Therefore, the aim of this study was to describe the prevalence of benzodiazepine 
use in Belgian nursing homes, with attention to indications and dosages for each of the commonly used drugs. 
Furthermore,  we compared actual dosages with recommended dosages  in older adults and explored the risk 
profile for chronic benzodiazepine use.  
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METHODS: 
 
Data for this secondary analysis study was obtained from a multicentre study, investigating the overall drug 
utilisation in Belgian nursing homes. A detailed description of the methods and findings of this study was published 
elsewhere [1, 29].   
Setting 
Belgium has a mixed, public/private health care system. The system is fee for service.  An essential principle of the 
Belgian health care system is the patient’s freedom of choice between a wide range of independent care providers 
without listing system. In particular, the Belgian long-term residential care structure consists of residential and/or 
nursing homes for older people, which offer a home replacement with or without nursing care. Governance of 
nursing homes for older people is either public (community health services) or private (predominantly non-profit). 
Each nursing home has a medical coordinator who is a general practitioner, additionally educated in care for older 
people. Most of the residents are still treated by their former GP, with an average of 32 visiting GPs per nursing 
home. Thereby, the GP has the responsibility for the treatment and medication policy. Periodic reassessment of the 
medication charts (i.e. a regime for monitoring and discontinuation of therapy) is not mandatory. 
Data collection 
The PHEBE study (Prescribing in Homes for the Elderly in BElgium) was a cross-sectional, descriptive study of a 
representative, stratified random sample of 76 Belgian nursing homes. Data collection at resident level included 
administrative, clinical and medication data. To score the activities of daily living (ADL), we used the Katz scale[30] 
which is a mandatory instrument in Belgian nursing homes. The progression of disorientation as proxy for dementia 
severity was also scored by this instrument, ranging from a score 1 (no dementia) to 5 (severe dementia).  
For collecting clinical data, a checklist  with 28 items, focusing on clinical problems (i. e. diseases with a clear cut 
diagnosis such as COPD, cardiovascular diseases,…) and on care problems (i.e problems with a predominant nursing 
care burden such as incontinence, pain, risk of falling,…) was send to the general practitioner (GP) of each included 
resident. The 28-item checklist of clinical conditions was ad hoc designed for this study, with the items selected 
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based on existing prescribing quality indicators for the elderly (BEERS, BEDNURS, ACOVE). It was pilot tested in two 
nursing homes. 
The GP received a printout of the medication chart for verification of the medication use, and was asked to tick a 
predefined list of main indications for each medication. Residents, considered by their GP as having a palliative 
status were excluded from the analysis. 
Classification of benzodiazepines  
Benzodiazepines (BZD), a group of psychoactive drugs with sedative, hypnotic, anxiolytic, anticonvulsant, muscle 
relaxant and amnesic action [5] were coded according to the Anatomical Therapeutic and Chemical classification 
[31]. We investigated the benzodiazepines, available on the Belgian pharmaceutical market of the ATC classes 
hypnotics (N05CD), anxiolytics (N05BA) and also the related z-drugs (N05CF).  This classification is not strictly linked 
to the clinical indication, as most of the benzodiazepines have a mix of different pharmacological actions. 
Clonazepam (N03AE01) mostly used for the indications ‘restless legs’ and ‘epilepsy’, and tetrazepam (M03BX07), 
used as a muscle relaxant, were not included in this study. Duplicate use therapy was defined as the concomitant 
use of 2 or more different benzodiazepines or z-drugs (BZD/Z). The focus of this study was chronic use, which was 
defined as daily use for at least 3 months. We analysed 2 levels of describing BZD/Z use: the prescription 
(medication) and the resident level. Indications were analysed at resident and prescription level and dosages at 
prescription level only.  
Indications and dosages 
The indication of each BZD/Z drug was obtained from the GP who ticked an item on a predefined list of indications: 
anxiety, insomnia, unrest, epilepsy, muscle tension and acute agitation. Only the indications anxiety, insomnia and 
unrest were analysed in depth, as the other indications were not prevalent enough. Unrest is the symptom 
targeted by mild sedatives, intended to calm a restless patient. It is to be distinguished from the narcotic sedation 
used in palliative setting. When a physician ticked 2 or more indications for the same BZD/Z, we classified this as 
‘multiple indications’. Only BZD/Zs with a minimum frequency of 15 prescriptions were reported in this study.  
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The daily dosage of each BZD/Z in each patient was recorded by summing the doses taken at the different 
moments of intake during one day. Comparison between prescribed daily dosages of a BZD/Z for different 
indications was made when at least 5 prescriptions for each indication were present. We also analysed the 
different moments of intake to see fractionation. 
Determination of the daily dose recommended not to exceed in older adults. 
Reviewing several international pharmaceutical sources with dose recommendations for older adults, we selected 3 
international formularia [21-23] and 3 explicit criteria for inappropriate prescribing for older adults [24-26] that 
mentioned detailed information per active substance. These sources were the basis of selecting ‘the geriatric upper 
limit’  i.e. daily dose recommended not to exceed in the geriatric population. We focused on specific doses 
associated with the indication ‘insomnia’ and ‘anxiety’ and selected the dose which was advised by the majority of 
the sources. Specific dose recommendations for sedative action in the indication of unrest were not found in these 
sources. 
Only for lorazepam, we found a dose separate for insomnia and for anxiety.  For alprazolam, bromazepam and 
prazepam, these sources only mentioned a dose for the indication of anxiety. For the indication of insomnia, we 
found specific dose recommendations for lormetazepam, zolpidem and zopiclone.  The recommendations retrieved 
from the various sources, the selected geriatric upper limit, and the relation with the Defined Daily Dose(DDD) and 
diazepam equivalent are presented in Box 1.   
To calculate the percentage of prescriptions exceeding the ‘geriatric upper limit’, we compared the actual daily 
dosages for each prescription identified in the study with the geriatric upper limit. 
Statistics 
The data was analysed using the statistical package SPSS version 18. The alpha level of significance was set at p< 
0.05.  
In a preliminary analysis investigating BZD and z-drug use separately, we found no differences in residents 
characteristics. Consequently, all users were concatenated in one “BZD/Z” group for further analysis.  
7 
 
We used descriptive statistics to explore indications and dosages. To detect differences in prescribed daily doses 
for different indications, we used non-parametric statistics (medians and the Mann-Whitney U test).  To explore a 
risk profile for BZD/Z use, we compared users and non-users. In univariate analysis, we used Chi² for dichotomous 
variables and independent T-tests for continuous variables. For multivariate analysis, we used a stepwise 
regression model with the statistically significant variables from the univariate analysis. To compare the 
characteristics of chronic users of BZD/Zs  in different indications (anxiety, insomnia, unrest),  we used Chi² for 
dichotomous variables and one way ANOVA for continuous variables. 
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RESULTS 
 
Description of the study population 
Medication data and clinical information of 1730 residents was included in the analysis. The mean age was 85 
(range 60-104) and 78% was female. In 48% of the population, the treating physician diagnosed dementia and in 
36% depression (table 1). A combination of these two care problems was seen in 15% of the residents. 
The residents had a mean drug utilisation of 7 chronic medications per resident, ranging from no medication (in 
less than 1% of the residents) to 22 medications. The most frequently used drugs were central nervous system 
drugs with benzodiazepines and z-drugs (BZD/Z), antidepressant, antipsychotic and anti-dementia drug prevalence 
in respectively 53%, 40%, 33% and 8% of all residents (table 1). 
Descriptive analysis on resident level: prevalence of BZD/Z users and indications. 
The prevalence of BZD/Z drug utilisation among Belgian nursing home residents (n=1730) was 53 % (n=918). 
Chronic use was present in 50% (n=859) of the residents, and 3% used a BZD/Z only occasionally. The use of a single 
chronic BZD/Z was seen in 42% of the residents, while 8% had 2 to 3 chronic BZD/Zs on their medication chart 
(table 2).  
Among the chronic users, using a single BZD/Z (n=729), indication was missing in 126 residents.  An analysis of the 
characteristics of residents with missing indication revealed no significant differences. Hence,  the distribution of 
indications was extrapolated to the group of chronic users of a single BZD/Z.  
The leading indication was insomnia (59%) followed by anxiety (17%), unrest (10%), and “other indications”(4%); 
the use of one BZD/Z for multiple indications was 10% (Table 2). When a resident received two or three chronic 
BZD/Zs, there was mostly a different indication for each of the prescribed BZD/Z, most often a mix of  anxiety,  
insomnia or unrest. 
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Descriptive analysis at prescription level: prevalence and dose analysis per indication 
The 859 residents on chronic BZD/Zs received a total of 1001 chronic BZD/Z prescriptions for different indications 
(table 3).  
On a total of 448 chronic prescriptions for insomnia, physicians prescribed 16 different BZD/Z drugs: 46% hypnotics 
(N05CD)  and 27% z-drugs (N05CF), but also 27% anxiolytics (N05BA). The dominant sleeping pill was the hypnotic 
lormetazepam (38%), followed by zolpidem (23%). On a total of 186 prescriptions to treat anxiety, physicians 
prescribed 13 different BDZ/Zs, predominantly anxiolytics (alprazolam 36% and lorazepam 27%). On a total of 94 
prescriptions to treat unrest, 16 different BZD/Zs were prescribed with a wide spread of anxiolytics (but 
predominantly lorazepam 39%)  and also some typical hypnotics and z-drugs (27%) (table 3). 
When comparing the dosages on the prescriptions of an individual BZD/Z used for different indications, the 
prescribed daily dosages in prescriptions for insomnia were similar to the dosages in prescriptions for unrest, while 
for anxiety the daily dosages were higher (table 3).  For the treatment of anxiety, the daily dosage is fractionated 
into 2 to 4 administrations per day in 37% of these prescriptions. For the treatment of unrest, we saw fractionation 
in only 8% and no fractionation for insomnia as all prescriptions mentioned one dose at bedtime.  
Compliance with ‘the Geriatric Upper Limit’.  
In table 4 we give the percentage of prescriptions with a dose higher than ‘the geriatric upper limit’. In the 
prescriptions for insomnia this limit was exceeded for lormetazepam in 95%, zolpidem in 82%,  zopiclone in 78% 
and for lorazepam in 35% of all chronic prescriptions. In the prescriptions for anxiety the ‘geriatric upper limit’ was 
also exceeded but not in such high percentages: for alprazolam in 30%, lorazepam in 12%, bromazepam in 11% and 
for prazepam in 5% of all chronic prescriptions. 
Comparison between  BZD/Z users and non-users. 
Univariate analysis showed that BZD/Z users had a significantly larger usage of chronic medications and 
antidepressants; a higher frequency of care problems such as constipation, depression, chronic pain; and a lower 
frequency of dementia and incontinence. We found no association between BZD/Z use and the physicians’ 
10 
 
perception of the risk of falling, nor with the frequency of clinical problems such as cardiovascular diseases, 
diabetes and COPD (table 5).   
In multivariate analysis, BZD/Z use was more frequent in female residents (OR 1.32 95%CI 1.03-1.68) and residents 
with chronic pain (OR 1.58 95%CI 1.27-1.97), constipation (OR 1.43 95%CI 1.16-1.76) and depression (OR 1.68 
95%CI 1.35-2.08), and less frequent in residents with incontinence (OR=0.71 95%CI 0.57-0.88) and dementia 
(OR=0.60 95%CI 0.48-0.74 (table 5).  
Comparison between BZD/Z users for the different indications.  
Depression, chronic medication, antidepressant and antipsychotic use was significantly more present when a 
resident took a BZD/Z for anxiety rather than for insomnia and unrest. We found no significant differences in the 
risk profile of residents with BZD/Z use for insomnia versus use for unrest (table 6).  
Especially among users with the indication of insomnia, we observed a gradual decrease in BZD/Z use as dementia 
progressed (figure 1). 
Relationship with institutional characteristics 
BZD/Z drug use was not associated with institutional characteristics such as private or public facility, size, or 
staffing.  
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DISCUSSION 
ORIGINALITY OF THE STUDY 
In this observational cross-sectional study of chronic use of benzodiazepines and z-drugs (BZD/Z) in Belgian nursing 
homes , the prevalence of usage of these drugs has been examined in depth per indication, as well as differences in 
dosing practices per indication.  
We confirmed the high prevalence of chronic BZD/Z use (half of the residents) in this setting, as found in numerous 
other studies [2, 4, 32]. We found that insomnia was the main indication for chronic use, and was treated at higher 
dosages than recommended in older adults [21, 23, 25, 26]. This finding is not striking, but our study is the first to 
scientifically confirm the assumption that insomnia is most prevalent for BZD/Z use. We were able to determine 
interesting elements for a risk profile of BZD/Z use in multivariate analysis, such as a positive associations with 
female gender, obstipation, depression, chronic pain, and polypharmacy (including polypharmacy with other 
psychotropics), and negative associations with dementia and incontinence.  There was a puzzling absence of 
association with age, risk of falling, clinical problems, and institutional characteristics.   
This study in a large representative sample of Belgian nursing home residents provides long-awaited information 
on indications and dosages of benzodiazepines [33]. Actual daily dosages were compared to the geriatric upper 
limit, a pragmatic threshold determined from authoritative international pharmaceutical sources.  
 
STRENGHTS AND LIMITATIONS 
Strength of our study was the substantial and representative sample of Belgian nursing home residents [29]. In 
addition, in neighbouring European countries [2-4] similar prevalence numbers of benzodiazepine use were found.  
In the United States [27], there is a lower use of benzodiazepines  due to the safety warnings issued in the late ’80 
and due to specific actions tackling the high use of these drugs (Medicare part D). Another strength of this study is 
that our data collection was based on reliable recording from primary sources,  namely medication charts and 
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direct clinical information from the treating GP. Another strong aspect of this study was our attempt to list most of 
the existing recommendations for older adults regarding dosages of BZD/Zs. However, we did not use an explicit 
method to extract the geriatric upper limit and we limited ourselves to the most abundantly prescribed BZD/Zs in 
Belgium. This geriatric upper limit is a threshold based on a pragmatic analysis of different sources, and therefore 
not a gold standard nor a rigid criteria for inappropriate prescribing. 
Another limitation was that we did not use internationally validated criteria to evaluate (severity of) dementia. In 
this cross-sectional study, we were not able to investigate the distribution of the duration of chronic use, nor it was 
possible to investigate temporal changes and the relationship between process and outcome. Indications of BZD/Z 
drugs were collected by interviewing the GP, which may have influenced data reliability. To reduce the complexity 
of the analysis, we narrowed our in depth analysis of indications to chronic users with only one BZD/Z and 
therefore only one indication, and disregarded residents on multiple BZD/Zs (8% of all residents) or residents on a 
BZD/Z with more than one indication (10% of the residents on a single chronic BZD/Z). On top there was a high 
number of missing indication data (17%) which might reflect an uncertainty of the treating GPs to discriminate 
between the indications of anxiety, insomnia, and unrest. This pragmatic approach might have introduced some 
bias in the estimation of the prevalence.   
 
CRITICAL DISCUSSION OF THE MAIN FINDINGS 
Insomnia  
Our study showed that the number one indication for BZD/Z drugs in this setting was insomnia, and to a far lesser 
extent anxiety and unrest.  
A striking finding was that almost all use of BDZ/Z drugs for insomnia was chronic, which is generally considered to 
be inappropriate [25, 34]. In order to avoid chronic prescribing, guidelines such as the British National Formulary 
and the Belgian drug code [21, 35] point out that before prescribing a hypnotic, the cause of the insomnia should 
be established and, where possible, underlying factors (such as depression or ‘restless legs’ ) should be treated [36, 
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37]. Establishing a good sleep hygiene is the first choice, but is not easy to implement in nursing homes. When a 
pharmacological treatment seems necessary, hypnotics should be reserved for short courses (<3weeks) in the 
acutely distressed and routine/chronic prescribing is undesirable [21]. 
With regard to the drug choice within the benzodiazepine drug class (with hypnotic, anxiolytic, -sedative, muscle-
relaxant and  amnesic action) in the indication of insomnia, mainly hypnotic benzodiazepines and z-drugs were 
used,  but also the anxiolytics lorazepam and bromazepam. 
With regard to dosages within the different indications, we found that especially in patients treated for insomnia, 
the daily dosages of the hypnotic benzodiazepines, of the z-drugs, and of the anxiolytic lorazepam exceeded the 
geriatric upper limit. However, in terms of diazepam equivalence, the dosages were still considerably lower than 
the dosages used when treating patients with anxiety. 
It is generally known that older adults need a dose reduction, but clear indication specific information about this 
reduction is hard to find. Most sources stay vague and point at a dose reduction of 50% and a slow titration. Hence, 
it is no surprise that there are no clear guidelines, and that GPs are not aware of geriatric optimal dosing. A 
comparison of the geriatric upper limit with the Defined Daily Dose (DDD)  revealed that for anxiety the two values 
coincided, but that for insomnia, the geriatric upper limit was half the DDD (BOX 1). This may be one  
methodological explanation for the high prevalence of exceeding dosages in prescriptions indicated for insomnia. 
Another explanation is that physicians titrate the dosage upwards when tolerance sets in, as expected for 
benzodiazepines use. Also, the culprit may be the unavailability of geriatric package dosages. Lormetazepam for 
example, is on the Belgian market in package doses of 1 or 2 mg, and consequently exceeds the required 0,5mg a 
day for older adults. This is also the case for the package dosages of zolpidem (only packages of 10mg on the 
market). 
In our study, the hypnotic users, but especially the residents receiving a BZD to treat anxiety were more associated 
with having a depression and a prescription for an antidepressant. This chronic concomitant use of psychotropic 
drugs to treat depression is not appropriate in the geriatric population who has already an increased risk of 
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interactions and adverse drug reactions. On the one hand, it is not surprising we found an association between 
depression and BZD/Z use, because depression can be the reason of initiating a BZD/Z drug, definitely when 
depression is related to a disturbed sleep pattern and anxiety [38]. On the other hand, a study in 2007 revealed 
that the use of hypnotics was associated with an increased incidence of depression, suggesting hypnotics may be 
contra indicated when there is a risk for depression [39]. 
Unexpectedly, we saw a gradual decrease in the use of sleeping pills when dementia progressed, although it is well 
known that patients with dementia often have nocturnally disturbed sleep [40]. As a sleeping problem is frequently 
an explicit complaint, uttered by the patient [41], it is possible that prescribing sleeping pills is demand-driven. So, 
when residents with severe dementia lose the ability to express the need for sleeping pills, their prescription might 
not get renewed.  
Anxiety  
In patients using only a single BZD/Z chronically, the single indication of anxiety was limited to less than 1 in 5 
patients. However, this indication was also present in patients using multiple BDZ/Z drugs, or a single BZD/Z drug 
for multiple indications. Using BZDs chronically to treat mild anxiety is considered to be inappropriate [8]. At the 
onset of treatment of depression, a benzodiazepine could be used as an adjuvant, as the anti-anxiety effect of 
some antidepressants can take 2 to 4 weeks  [42]. However, to avoid chronic use, this dual therapy should be 
tapered in time [43]. 
In this indication, the drugs of choice were exclusively the anxiolytic ATC-class drugs, used in daily dosages higher 
than the dosages used when indicated for insomnia, but closer to the geriatric upper limit (and to the DDD). It is 
logical daily dosages are higher for anxiety as they are more frequently dispensed during the day, unlike for 
sleeping pills, which are administered once daily in the evening.  
The indication of anxiety was associated with a more intense polypharmacy, more antidepressants (and more 
depression), and more antipsychotics. Hence, efforts to withdraw from BDZ/Z drug usage should be seen in the 
broader context of mental health, and treatment of behavioural and psychological symptoms of dementia.  
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Unrest  
A variety of benzodiazepines in different ATC classes were used to treat this indication. The prescribed daily doses 
of these BZD/Z drugs for the indication ‘unrest’ were similar to the prescribed daily doses of these BZD/Z drugs 
used for the treatment of insomnia. Furthermore, we observed no differences in characteristics between a resident 
using a BZD/Z drug for insomnia and unrest. Sedative action is in this setting considered to provide calming effects 
(different from the narcotic aim in palliative care context and different from control of acute agitation). This 
suggests  some semantic overlap between the terms “sedative” and “hypnotic” action, not only in literature but 
also in daily practice.  
Risk profile of BDZ/Z drug users 
Our multivariate comparison of users versus non-users revealed a positive associations with care problems such as 
obstipation and chronic pain, possible causes of irritation and sleeplessness leading to BZD/Z use. The negative 
association between incontinence and BZD/Z use might be explained by covariance with dementia and the use of 
nocturnal incontinence material. 
The association with polypharmacy (more specifically psychotropic polypharmacy) calls for comprehensive 
approach to assure the quality of psychotropic pharmacotherapy of mental health in nursing homes [44]. 
In other studies an association was found between BZD/Z use and risk of falling [20, 45-47]. In this cross-sectional 
study we could not observe this, possibly because treating physicians failed to perceive the risk of falling as a 
consequence of BZD/Z use, or because of the multifactorial nature of this association.   
We did not find significant associations between BDZ/Z drug use and institutional characteristics (including 
staffing), contradicting the popular belief that high hypnotic usage is associated with low staffing [48].   
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IMPLICATIONS FOR PRACTICE AND  RESEARCH 
The contradiction between recommendations against long-term use,  and the high prevalence in older adults has 
already been often discussed but seldom explained.  Prescribers seem to be convinced of the detrimental long-
term effects of benzodiazepines in older adults [49]. But it seems very hard to change habitual prescribing and to 
overcome the fear of possible relapse and withdrawal effects in both prescribers and caregivers as in patients [50].   
It is difficult to persuade patients and their physicians to stop chronic use of BDZ/Z drugs.  However, a small 
intervention study in primary care showed that sending a letter from the physician to the BZD/Z user could have a 
positive impact on successful withdrawal [51, 52]. Motivation and gradual tapering seems to be the best strategy 
for discontinuation [11, 53]. 
Previous articles on BZDs supported non-pharmacological ways to solve insomnia and to avoid the initiation of 
benzodiazepines use [54-56]. More efforts to motivate the residents as well as the care giving staff to do physical 
exercises and other activities to ameliorate the sleep quality of older adults must be made in order to reduce the 
persistent sleep problems and sleeping pill use [57, 58]. 
More emphasis should be given to at least avoid high dosages in chronic use for older patients.  This study found 
that prescribers do not pay attention to reduce the dosage according to existing recommendations, especially in 
patients treated for insomnia. We do not know whether this reluctance indirectly leads to a higher mortality [59], 
but several studies state the existence of adverse effects, such as cognitive impairment [14, 15] addictive 
properties and possible withdrawal effects. The pharmaceutical companies  should produce packages with 
appropriate dosages for older adults. But also nurses and pharmacists could play an important role in the correct 
administration of these drugs in older adults [60, 61]. 
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Future research  on benzodiazepines should differentiate between insomnia and anxiety or other indications. Our 
findings suggest that insomnia, given its high prevalence as primary indication,  deserves priority. Efforts to reduce 
chronic use should concentrate on reducing initiation, chronic use and too high dosages for this indication. 
Furthermore, there is a need to strengthen the evidence base for the absence of long-term efficacy and the 
importance of adverse effects, in order to persuade physicians, nurses, caregivers and the patients of the positive 
risk benefit balance of discontinuation attempts. 
 
 
COMPETING INTEREST 
There are no competing interests to declare. 
 
ACKNOWLEDGEMENTS 
We thank prof. Dr. Thierry Christiaens, from the department of family medicine and primary care and Dr. Hans 
Debruyne, psychiatrist at the  Dr. Guislain Centre for Psychiatry for their contribution. 
 
18 
 
TABLES AND FIGURES 
TABLE 1: Description of the study population 
RESIDENT CHARACTERISTICS 
Total 
population 
  n= 1730 
Demographical characteristics   
Age (mean+range) 84.8 [60-104] 
Gender (% female) 78.1 
  
Main clinical problems(%) 
 
cardiovascular  75.7 
Peptic ulcer 24.6 
COPD 17.2 
Diabetes 16.8 
Renal failure 12.6 
Hepatic problems 1.4 
  
Main care problems(%)  
Dementia 47.7 
Insomnia 44.0 
Constipation 41.9 
Incontinence 35.9 
Depression 35.7 
Chronic pain 35.1 
Risk of falling 45.5 
  
Medication information  
Number of (mean+range)  
Medications  8.0 [0-22] 
Chronic medications 7.1 [0-22] 
Prevalence of overall psychotropic 
use(%) 
77.5 
Antipsychotics 32.9 
Antidepressants 39.5 
BZD/Z 53.1 
Anti-dementia drugs 7.5 
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TABLE 2: Prevalence of users of benzodiazepines and z-drug use (BZD/Z) among 1730 nursing 
home residents and distribution of chronic users of a single BD/Z per indication. 
Prevalence of BZD/ Z use (n=1730)
BZD/Z users 53.1%
Chronic BDZ/Z users 49.7%
Chronic users of a single BZD/Z 42.1%
Distribution of indications among single chronic BZD/Z users (n=603*)
Insomnia 58.7%
Anxiety 17.4%
Unrest 10.4%
Others** 3.6%
Multiple indications 9.8%
 *729 residents receiving a single chronic BZD/Z corrected for 126 missing indications
** Epilepsy, muscle spasm, panic attack   
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TABLE 3:  Distribution of prescriptions for chronic BZD/Z drug use and median prescribed daily 
doses per indication and per active substance.  
 
ATC-DRUG CLASS P value
TOTAL INSOMNIA ANXIETY UNREST
% (n=1001)  % (n=448) % (n=186) % (n=94) mg min-max mg min-max mg min-max
ANXIOLYTICS = N05BA 48.8 26.8 96.8 73.4
-lorazepam 22.1 19.6 26.9 39.4 1.0 0.25-2.50 2.0 0.50-7.50 1.25 0.50-2.50 0.035
-alprazolam 10.3 0.4 36.0 8.5 0.5 0.07-2.00 0.375 0.13-1.00 0.087
-bromazepam 4.1 4.0 4.8 5.3 4.5 3.00-6.00 6.0 3.00-12.00 0.196
-prazepam 3.3 0.0 11.8 0.0 30.0 5.00-40.00
other 9.0* 2.8 17.3 20.2
HYPNOTICS = N05CD 33.0 46.4 3.2 18.1
-lormetazepam 26.1 37.7 2.7 12.8 2.0 0.50-3.00 1.75 0.50-2.00 0.832
other 6.9** 8.7 0.5 5.3
Z-DRUGS = N05CF 18.3 26.8 0.0 8.5
-zolpidem 16.3 22.5 0.0 7.4 10.0 2.50-20.00 10.0 5.00-10.00 0.853
-zopiclone 1.9 4.0 0.0 1.1 7.5 3.75-7.50
-zaleplon 0.1 0.2 0.0 0.0
**other hypnotics: botizolam (2.6%); flunitrazepam (1.3%); triazolam (1.3%); flurazepam (0.9%); loprazolam (0.6%); nitrazepam (0.2%)
*** differences between Prescribed daily doses (Mann-Withney U); lorazepam differences only between insomia and anxiety
*other anxiolytics: oxazepam (2.1%); diazepam (2.0%); chlorazepate (1.9%); clotiazepam (1.5%) cloxazolam (1.1%); ethylloflazepam (0.2%), 
clobazan (0.1%), nordazepam (0.1%)
Chronic prescriptions of BZD/Z Prescribed dialy doses (MEDIAN-RANGE)
INSOMNIA ANXIETY UNREST
***
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TABLE 4: Percentage of prescriptions exceeding the Geriatric Upper Limit per indication.  
INDICATION BZD/Z DOSAGES 
  
  
Geriatric Upper 
Limit* 
n**  %Exceeding*** 
INSOMNIA Lormetazepam 0.5mg 169 94.7 
Zolpidem 5mg 101 82.2 
Lorazepam 2mg 88 35.2 
 Zopiclone 3.75mg 18 77.8 
     
ANXIETY Alprazolam 0.75mg 67 29.9 
Lorazepam 3mg 50 12.0 
Prazepam 30mg 22 4.5 
Bromazepam 10mg 9 11.1 
*Recommendations (see box) 
** the number of chronic prescriptions for this specific drug for this indication 
*** % of prescriptions for older adults exceeding the Geriatric Upper Limit 
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TABLE 5: Comparison of characteristics between chronic benzodiazepine or z-drug users and 
non-users (n=1730). 
 
RESIDENT CHARACTERISTICS  BZD/Z user non user P value*
n=859 n=871 OR 95%CI OR 95%CI
Demographical
Age (mean+range)  84.5[60-104] 85.1[60-104] 0.165 0.99 0.98-1.00
Gender(% female) 80.3 75.7 0.021 1.31 1.04-1.65 1.32 1.03-1.68
Main clinical problems(%)
Cardiovascular 77.3 74.1 0.112 1.20 0.96-1.49
Peptic ulcer 24.9 24.3 0.766 1.03 0.83-1.29
COPD 18.5 15.9 0.156 1.20 0.99-1.54
Diabetes 15.9 17.8 0.303 0.88 0.68-1.13
Renal failure 11.8 13.4 0.326 0.87 0.65-1.15
Hepatic problems 1.6 1.2 0.441 1.38 0.61-3.12
Main care problems(%)
Constipation 46.8 36.9 p<0.001 1.50 1.24-1.82 1.43 1.16-1.76
Risk of falling 46.4 44.5 0.421 1.08 0.89-1.31
Depression 42.2 29.0 p<0.001 1.79 1.46-2.20 1.68 1.35-2.08
Chronic pain 42.1 27.9 p<0.001 1.89 1.54-2.31 1.58 1.27-1.97
Dementia 40.1 55.5 p<0.001 0.54 0.44-0.65 0.60 0.48-0.74
Incontinence 32.1 39.7 0.001 0.72 0.59-0.88 0.71 0.57-0.88
Medication information
Number of (mean+range)
Medications 9.0[0-22] 7.0[1-22] P<0.001 1.15 1.12-1.19
Chronic medications 7.7[0-22] 6.2[0-22] P<0.001 1.18 1.15-1.22
Use of psychotropic's(%) 100.0 54.6 P<0.001
Antipsychotics 35.0 30.8 0.065 1.21 0.99-1.48
Antidepressants 48.3 32.4 P<0.001 1.95 1.61-2.37
UNIVARIATE ** MULTIVARIATE***
* P value of the difference between user and non-user using χ² for categorical variables and independent t-test for 
continuous variables
**odds ratio: Risk of taking a BZD/Z
*** stepwise regression model (covariates: gender,constipation,depression,pain,dementia,incontinence)  
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 TABLE 6 : Comparison of  characteristics of chronic benzodiazepine and z-drug users for the 
indications ‘insomnia’, ‘anxiety’ and ‘unrest’. 
 
 
RESIDENT CHARACTERISTICS
Chronic BZD/Z 
user INSOMNIA
Chronic BZD/Z 
user ANXIETY
Chronic BZD/Z 
user UNREST
(n= 354)* (n=105)* (n= 63)*
Demographical
Age (mean+range) 85.5 [60-102] 84.9 [60-99] 83.6 [60-103] 0.224
Gender(% female) 80.5 78.8 74.6 0.562
Main care problems(%)
Constipation 47.0 54.3 49.2 0.423
Risk of falling 48.0 51.9 50.8 0.752
Depression 36.3 61.2 28.3 P<0.001
Chronic pain 41.6 47.6 44.4 0.542
Dementia 36.0 43.1 41.9 0.343
Incontinence 31.5 28.8 33.3 0.811
Medication information
Number of (mean+range)
Medications 8.4 [1-20] 10.0 [2-21] 9.1 [3-17] P<0.001
Chronic medications 7.5 [1-16] 8.9 [2-21] 8.1 [3-15] P<0.001
Use of psychotropic's(%)
Antipsychotics 25.4 38.1 34.9 0.024
Antidepressants 39.5 61.9 36.5 P<0.001
**  P value of differences using χ² for dichotomous variates and one way Anova for continuous variates
* residents receiving a single BZD/Z for this specific indication
P value **
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FIGURE 1: Indication split benzodiazepine and z-drug use in relation to increasing dementia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEMENTIA STAGES (KATZ) 
Stage 1: no dementia (n=542) 
Stage 2 (n=402) 
Stage 3 (n=438) 
Stage 4 (n=264) 
Stage 5: severe dementia (n=66) 
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Box: 
 
We based our selected dose adaptations on 3 formularia and 3 explicit criteria about inappropriate prescribing in the elderly:
formularia explicit criteria
Britisch National Formularium (BNF) (United Kingdom) BEERS 2003 (USA)
the Martindale 36ste edition (2009) Rancourt 2004 (Canada)
Informatorium medicamentorum 2009 (the Netherlands) Laroche 2007 (France)
Recommended daily doses were investigated for the most relevant BZD/Z and for the indications insomnia and anxiety.
ALPRAZOLAM BROMAZEPAM PRAZEPAM LORMETAZEPAM ZOLPIDEM ZOPICLONE
insomnia anxiety anxiety anxiety anxiety insomnia insomnia insomnia
BNF 1mg 2mg 0.75mg * * 0.5mg 5mg 3.75mg
Martindale 2mg 3mg 0.75mg 9mg 30mg 0.5mg 5mg 3.75mg
Inform. Medica 2mg 4mg 0.75mg 10mg 30mg 1mg * 3.75mg
BEERS * 3mg 2mg * * * * *
Rancourt * 3mg 0.75mg * * * * *
Laroche * 3mg 2mg * * 0.5mg 5mg 3.75mg
Geriatric upper 
limit (in mg/day)
2mg 3mg 0.75mg 10mg 30mg 0.5mg 5mg 3.75mg
 - DDD 0,8 1,2 0,75 1 1 0,5 0,5 0,5
- Diazepam 
equivalent
20mg 30mg 15mg 20mg 20mg 3,3mg 2,5mg 2,5mg
* the BZD has no recommended doses for this indication or the BZD/ Z is not listed in the formularium/explicit criteria
GERIATRIC UPPER LIMIT
RECOMMENDED DAILY DOSES NOT TO EXCEED IN OLDER ADULTS
LORAZEPAM
Geriatric upper limit expressed in
Sources
 
26 
 
References 
1 Azermai M, Elseviers M, Petrovic M, Van Bortel L, Stichele RV (2011) Geriatric drug utilisation of 
psychotropics in Belgian nursing homes. Hum Psychopharmacol  DOI 10.1002/hup.1160 
 
2 Gobert M, D'Hoore W (2005) Prevalence of psychotropic drug use in nursing homes for the aged 
in Quebec and in the French-speaking area of Switzerland. International Journal of Geriatric 
Psychiatry 20 (8): 712-721 DOI 10.1002/gps.1349 
 
3 Hosia-Randell H, Pitkala K (2005) Use of psychotropic drugs in elderly nursing home residents 
with and without dementia in Helsinki, Finland. Drugs & Aging 22 (9): 793-800 DOI 2298 [pii] 
 
4 Petek Ster M, Cedilnik Gorup E (2011) Psychotropic medication use among elderly nursing home 
residents in Slovenia: cross-sectional study. Croat Med J 52 (1): 16-24 
 
5 Ashton H (1994) GUIDELINES FOR THE RATIONAL USE OF BENZODIAZEPINES - WHEN AND WHAT 
TO USE. Drugs 48 (1): 25-40 
 
6 Neutel CI (2005) The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 17 (3): 
189-197 DOI K4246L51U2309218 [pii] 10.1080/09540260500071863 
7 Canadian Agency for Drugs and Technologies in Health (CADTH). Benzodiazepines in Older 
Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. 2010.AVAILABLE 
from http://www.cadth.ca/media/pdf:M0022_Benzodiazepines_Elderly.pdf. accessed: 10 August 
2011 
 
8 National Institute for Health an Clinical Excellence (NICE). Generalised anxiety disorder and panic 
disorder (with or without agoraphobia) in adults.January 2011. guidelines. Available from: 
http//www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf. Accessed 10 August, 2011. 
 
9 Martin JL, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C (2007) 
Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a 
systematic review and meta-analysis of clinical trials. Journal of Psychopharmacology 21 (7): 774-
782 DOI 21/7/774 [pii] 10.1177/0269881107077355 
10 Beland SG, Preville M, Dubois MF, Lorrain D, Voyer P, Bosse C, Grenier S, Moride Y (2010) The 
association between length of benzodiazepine use and sleep quality in older population. 
International Journal of Geriatric Psychiatry  DOI 10.1002/gps.2623 
 
11 Lader M, Tylee A, Donoghue J (2009) Withdrawing benzodiazepines in primary care. Cns Drugs 
23 (1): 19-34 DOI 10.2165/0023210-200923010-00002 2312 [pii] 
12 Voyer P, Preville M, Cohen D, Berbiche D, Beland SG (2010) The prevalence of benzodiazepine 
dependence among community-dwelling older adult users in Quebec according to typical and 
atypical criteria. Can J Aging 29 (2): 205-213 DOI S0714980810000115 [pii] 
10.1017/S0714980810000115 
27 
 
13 Verdoux H, Lagnaoui R, Begaud B (2005) Is benzodiazepine use a risk factor for cognitive decline 
and dementia? A literature review of epidemiological studies. Psychological Medicine 35 (3): 
307-315 DOI 10.1017/s0033291704003897 
 
14 Wu CS, Wang SC, Chang IS, Lin KM (2009) The Association Between Dementia and Long-Term 
Use of Benzodiazepine in the Elderly: Nested Case-Control Study Using Claims Data. American 
Journal of Geriatric Psychiatry 17 (7): 614-620 
 
15 Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Cognitive effects of long-term 
benzodiazepine use - A meta-analysis. Cns Drugs 18 (1): 37-48 
 
16 Klotz U (1998) Effect of age on pharmacokinetics and pharmacodynamics in man. International 
Journal of Clinical Pharmacology and Therapeutics 36 (11): 581-585 
 
17 Petrovic M, Mariman A, Warie H, Afschrift M, Pevernagie D (2003) Is there a rationale for 
prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg 58 (1): 27-
36 
 
18 Madhusoodanan S. BOJ (2004) Safety of benzodiazepines in the geriatric population. Expert 
Opinion on Drug Safety 3 (5): 485–493 
19 Cook PJ, Huggett A, Graham-Pole R, Savage IT, James IM (1983) Hypnotic accumulation and 
hangover in elderly inpatients: a controlled double-blind study of temazepam and nitrazepam. Br 
Med J (Clin Res Ed) 286 (6359): 100-102 
 
20 Mustard CA, Mayer T (1997) Case-control study of exposure to medication and the risk of 
injurious falls requiring hospitalization among nursing home residents. Am J Epidemiol 145 (8): 
738-745 
 
21 The British National Formularium (BNF). British Medical Association and the Royal 
Pharmaceutical Society. Available from http://bnf.org:bnf:index.htm  Accessed 10 August 2011 
 
22 KNMP. Royal Dutch Society of Pharmacy [in Dutch: Informatorium Medicametorum. Koninklijke 
Nederlandse Maatschappij ter bevordering van de Farmacie] (2009) Available from: 
www.knmp.nl  Accessed 8 June 2011 
  
23 The Martindale: The Complete Drug Reference, 36th edition. Sweetman S.C. 
editor:  Pharmaceutical Press. 
 
24 Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH (2003) Updating the Beers 
criteria for potentially inappropriate medication use in older adults: results of a US consensus 
panel of experts. Arch Intern Med 163 (22): 2716-2724 DOI 
10.1001/archinte.163.22.2716163/22/2716 [pii] 
25 Rancourt C MJ, Baillargeon L, Verreault R, Laurin D, Grégoire JP. (2004) Potentially inappropriate 
prescriptions for older patients in long-term care. BMC Geriatrics 4 (9) 
28 
 
26 Laroche ML, Charmes JP, Merle L (2007) Potentially inappropriate medications in the elderly: a 
French consensus panel list. European Journal of Clinical Pharmacology 63 (8): 725-731 DOI 
10.1007/s00228-007-0324-2 
 
27 Stevenson DG, Decker SL, Dwyer LL, Huskamp HA, Grabowski DC, Metzger ED, Mitchell SL (2010) 
Antipsychotic and Benzodiazepine Use Among Nursing Home Residents: Findings From the 2004 
National Nursing Home Survey. American Journal of Geriatric Psychiatry 18 (12): 1078-1092 DOI 
10.1097/JGP.0b013e3181d6c0c6 
 
28 Holmquist IB, Svensson B, Hoglund P (2003) Psychotropic drugs in nursing- and old-age homes: 
relationships between needs of care and mental health status. European Journal of Clinical 
Pharmacology 59 (8-9): 669-676 DOI 10.1007/s00228-003-0679-y 
 
29 Elseviers M. VSR, Soenen K., Gobert M., Van Bortel L., Van De Voorde C. (2010) Drug utilisation in 
Belgian nursing homes: impact of residents' and institutional characteristics. Pharmacoepidemiol 
Drug Safety 19: 1041-1048 
 
30 Katz S, Akpom CA (1976) 12. Index of ADL. Med Care 14 (5 Suppl): 116-118 
 
31 ATC/DDD system. WHO Collaborating Centre for Drug Statistics Methodology.2009; available 
from: http://www.whocc.no  Accessed 20June 2011 
 
32 Westbury J, Jackson S, Gee P, Peterson G (2010) An effective approach to decrease antipsychotic 
and benzodiazepine use in nursing homes: the RedUse project. International Psychogeriatrics 22 
(1): 26-36 DOI 10.1017/s1041610209991128 
 
33 Bartlett G, Abrahamowicz M, Tamblyn R, Grad R, Capek R, du Berger R (2004) Longitudinal 
patterns of new Benzodiazepine use in the elderly. Pharmacoepidemiology and Drug Safety 13 
(10): 669-682 DOI 10.1002/pds.908 
 
34 Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D (2008) STOPP (Screening Tool of Older 
Person's Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment). 
Consensus validation. International Journal of Clinical Pharmacology and Therapeutics 46 (2): 72-
83 
 
35 BCFI (2010) Belgian Centre for Pharmacotherapeutic information. available from 
http://www.bcfi.be/  Accessed 8 June 2011 
36 B Terluin FBVH, K Van der Meer, G J H Neomagus, J Hekman, L P J Aulbers, J S Starreveld and M H 
Grol (2009) NHG-Standaarden Angststoornissen In: NHG-Standaarden voor huisartsened. 
Nederlandse huisartsen genootschap. 
 
37 Morin AK (2006) Strategies for treating chronic insomnia. Am J Manag Care 12 (8 Suppl): S230-
245 DOI 3137 [pii] 
 
29 
 
38 van Vliet P, van der Mast RC, van den Brock M, Westendorp RGJ, de Craen AJM (2009) Use of 
benzodiazepines, depressive symptoms and cognitive function in old age. International Journal 
of Geriatric Psychiatry 24 (5): 500-508 DOI 10.1002/gps.2143 
 
39 Kripke DF (2007) Greater incidence of depression with hypnotic use than with placebo. BMC 
Psychiatry 7: 42 DOI 1471-244X-7-42 [pii] 10.1186/1471-244X-7-42 
40 Bliwise DL (2004) Sleep disorders in Alzheimer's disease and other dementias. Clin Cornerstone 6 
Suppl 1A: S16-28 
 
41 Cook JM, Marshall R, Masci C, Coyne JC (2007) Physicians' perspectives on prescribing 
benzodiazepines for older adults: a qualitative study. Journal of General Internal Medicine 22 (3): 
303-307 DOI 10.1007/s11606-006-0021-3 
 
42 Manji HK, Drevets WC, Charney DS (2001) The cellular neurobiology of depression. Nat Med 7 
(5): 541-547 DOI 10.1038/87865 87865 [pii] 
43 Cloos JM, Ferreira V (2009) Current use of benzodiazepines in anxiety disorders. Curr Opin 
Psychiatry 22 (1): 90-95 DOI 10.1097/YCO.0b013e32831a473d00001504-200901000-00016 [pii] 
44 Ruths S, Straand J, Nygaard HA (2003) Multidisciplinary medication review in nursing home 
residents: what are the most significant drug-related problems? The Bergen District Nursing 
Home (BEDNURS) study. Qual Saf Health Care 12 (3): 176-180 
 
45 Berdot S, Bertrand M, Dartigues JF, Fourrier A, Tavernier B, Ritchie K, Alperovitch A (2009) 
Inappropriate medication use and risk of falls--a prospective study in a large community-dwelling 
elderly cohort. BMC Geriatrics 9: 30 DOI 1471-2318-9-30 [pii]10.1186/1471-2318-9-30 
46 Ensrud KE, Blackwell TL, Mangione CM, Bowman PJ, Whooley MA, Bauer DC, Schwartz AV, 
Hanlon JT, Nevitt MC (2002) Central nervous system-active medications and risk for falls in older 
women. J Am Geriatr Soc 50 (10): 1629-1637 DOI jgs50453 [pii] 
 
47 Boyle N, Naganathan V, Cumming RG (2010) Medication and falls: risk and optimization. Clin 
Geriatr Med 26 (4): 583-605 DOI S0749-0690(10)00055-8 [pii]10.1016/j.cger.2010.06.007 
48 Svarstad BL, Mount JK (2001) Chronic benzodiazepine use in nursing homes: effects of federal 
guidelines, resident mix, and nurse staffing. J Am Geriatr Soc 49 (12): 1673-1678 DOI 49278 [pii] 
 
49 Anthierens S, Pasteels I, Habraken H, Steinberg P, Declercq T, Christiaens T (2010) Barriers to 
nonpharmacologic treatments for stress, anxiety, and insomnia Family physicians' attitudes 
toward benzodiazepine prescribing. Can Fam Phys 56 (11): E398-E406 
 
50 Iliffe S, Curran HV, Collins R, Kee SCY, Fletcher S, Woods B (2004) Attitudes to long-term use of 
benzodiazepine hypnotics by older people in general practice: findings from interviews with 
service users and providers. Aging & Mental Health 8 (3): 242-248 DOI 
10.1080/13607860410001669778 
 
30 
 
51 Cormack MA, Owens RG, Dewey ME (1989) The effect of minimal interventions by general 
practitioners on long-term benzodiazepine use. J R Coll Gen Pract 39 (327): 408-411 
 
52 Gorgels WJ, Oude Voshaar RC, Mol AJ, van de Lisdonk EH, van Balkom AJ, van den Hoogen HJ, 
Mulder J, Breteler MH, Zitman FG (2005) Discontinuation of long-term benzodiazepine use by 
sending a letter to users in family practice: a prospective controlled intervention study. Drug and 
Alcohol Dependence 78 (1): 49-56 DOI S0376-8716(04)00261-3 
[pii]10.1016/j.drugalcdep.2004.09.001 
53 Denis C, Fatseas M, Lavie E, Auriacombe M (2006) Pharmacological interventions for 
benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst 
Rev 3: CD005194 DOI 10.1002/14651858.CD005194.pub2 
 
54 Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL (2006) Psychological and 
behavioral treatment of insomnia:update of the recent evidence (1998-2004). Sleep 29 (11): 
1398-1414 
 
55 Mendelson WB (1995) Long-term follow-up of chronic insomnia. Sleep 18 (8): 698-701 
 
56 Bain KT (2006) Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother 4 
(2): 168-192 DOI S1543-5946(06)00028-6 [pii]10.1016/j.amjopharm.2006.06.006 
57 Alessi CA, Schnelle JF (2000) Approach to sleep disorders in the nursing home setting. REVIEW 
ARTICLE. Sleep Med Rev 4 (1): 45-56 DOI S1087-0792(99)90066-7 [pii]10.1053/smrv.1999.0066 
58 Lyne J, Quinlivan L, Byrne CA, Malone K, Walsh C (2011) Sleep hygiene use in a psychiatry 
outpatient setting. Ir Med J 104 (2): 49-50 
 
59 Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M (2009) A systematic review of research 
examining benzodiazepine-related mortality. Pharmacoepidemiology and Drug Safety 18 (2): 93-
103 DOI 10.1002/pds.1694 
 
60 Anthierens S, Grypdonck M, De Pauw L, Christiaens T (2009) Perceptions of nurses in nursing 
homes on the usage of benzodiazepines. J Clin Nurs 18 (22): 3098-3106 DOI JCN2758 
[pii]10.1111/j.1365-2702.2008.02758.x 
61 Verrue CL, Petrovic M, Mehuys E, Remon JP, Vander Stichele R (2009) Pharmacists' interventions 
for optimization of medication use in nursing homes : a systematic review. Drugs & Aging 26 (1): 
37-49 DOI 10.2165/0002512-200926010-000032613 [pii] 
 
 
